Stryker Co. (NYSE:SYK) Position Increased by Kingsview Wealth Management LLC – Slater Sentinel

Posted: Published on February 5th, 2020

This post was added by Alex Diaz-Granados

Kingsview Wealth Management LLC raised its holdings in shares of Stryker Co. (NYSE:SYK) by 85.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,642 shares of the medical technology companys stock after buying an additional 4,442 shares during the period. Kingsview Wealth Management LLCs holdings in Stryker were worth $2,026,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Garrett Wealth Advisory Group LLC acquired a new position in Stryker in the 3rd quarter worth approximately $35,000. Hudock Capital Group LLC boosted its stake in Stryker by 123.5% in the 4th quarter. Hudock Capital Group LLC now owns 181 shares of the medical technology companys stock worth $38,000 after purchasing an additional 100 shares during the period. Evoke Wealth LLC acquired a new position in Stryker in the 3rd quarter worth approximately $42,000. Horan Capital Advisors LLC. acquired a new position in Stryker in the 3rd quarter worth approximately $43,000. Finally, Institutional & Family Asset Management LLC boosted its stake in Stryker by 169.3% in the 3rd quarter. Institutional & Family Asset Management LLC now owns 202 shares of the medical technology companys stock worth $44,000 after purchasing an additional 127 shares during the period. Hedge funds and other institutional investors own 73.29% of the companys stock.

A number of equities analysts recently commented on the stock. Robert W. Baird raised their price objective on shares of Stryker from $242.00 to $248.00 and gave the stock an outperform rating in a research note on Wednesday, January 29th. Evercore ISI raised shares of Stryker from an in-line rating to an outperform rating in a research note on Thursday, January 2nd. Piper Sandler lowered shares of Stryker from an overweight rating to a neutral rating and set a $210.00 price objective for the company. in a research note on Tuesday, January 7th. Piper Jaffray Companies lowered shares of Stryker from an overweight rating to a neutral rating and set a $210.00 price objective for the company. in a research note on Tuesday, January 7th. Finally, Cantor Fitzgerald reaffirmed a neutral rating on shares of Stryker in a research note on Wednesday, January 29th. Seven investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Stryker presently has an average rating of Buy and an average price target of $227.45.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $2.49 earnings per share (EPS) for the quarter, beating analysts consensus estimates of $2.46 by $0.03. The company had revenue of $4.13 billion during the quarter, compared to analyst estimates of $4.11 billion. Stryker had a net margin of 13.99% and a return on equity of 25.75%. The companys revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the business posted $2.18 EPS. Equities research analysts expect that Stryker Co. will post 9.1 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st were issued a dividend of $0.575 per share. The ex-dividend date of this dividend was Monday, December 30th. This represents a $2.30 dividend on an annualized basis and a dividend yield of 1.09%. This is an increase from Strykers previous quarterly dividend of $0.52. Strykers dividend payout ratio (DPR) is currently 27.85%.

In other news, COO Timothy J. Scannell sold 4,666 shares of the firms stock in a transaction on Monday, November 18th. The shares were sold at an average price of $206.28, for a total transaction of $962,502.48. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 7.20% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: What is the Book Value of a Share?

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

See the rest here:
Stryker Co. (NYSE:SYK) Position Increased by Kingsview Wealth Management LLC - Slater Sentinel

Related Posts
This entry was posted in Medical Technology. Bookmark the permalink.

Comments are closed.